A
Alcista
Alcista · 25%CV
$5.79
Precio del escenario
$6.990
+0.195 (+2.79%)Al cierre
Loading chart…
- Máximo
- 7.180
- Apertura
- 6.720
- Precio medio ponderado por volumen
- 6.94
- Volumen
- 320.23K
- Capitalización
- —
- Mínimo
- 6.660
- Importe
- 2.22M
- EV/EBITDA, TTM
- -8.69
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.
Análisis de IA of CapsoVision Inc (CV)
ComprarCapsoVision Inc is a good buy right now due to its recent FDA clearance for an AI-assisted tool, which could enhance its market position, and a 10% revenue growth in Q2 2026. The current price is $6.99, and the RSI is at 74.861, indicating strong momentum. However, the main risk is the negative net income of -7,481,000 USD reported in Q2 2026, which investors should consider.
Métricas de valoración
El PER previsto actual de CapsoVision Inc (CV) es 0.00, frente a su media de 5 años de -10.86.
Escenarios de precio de Alphio AI para CV
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
5.009-28NASDAQ.COMCapsoVision Receives FDA Clearance for AI-Assisted Tool
9.009-28NASDAQ.COMCapsoVision Receives FDA Clearance for AI-Assisted Tool
9.508-14Yahoo FinanceCapsoVision Reports 10% Revenue Growth in Q2 2026
9.508-04NASDAQ.COMCRISPR Therapeutics Reports Narrowed Loss in Q2 2026
5.008-04NASDAQ.COMCapsoVision Launches AI Highlights for Capsule Endoscopy Studies
Preguntas frecuentes sobre CV, respondidas por Alphio AI
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule. It operates in the Healthcare sector.
CapsoVision Inc is a good buy right now due to its recent FDA clearance for an AI-assisted tool, which could enhance its market position, and a 10% revenue growth in Q2 2026. The current price is $6.99, and the RSI is at 74.861, indicating strong momentum. However, the main risk is the negative net income of -7,481,000 USD reported in Q2 2026, which investors should consider.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.